Collaborative Group On Drug Use In Pregnancy C. An international survey on drug utilization during pregnancy. Int J risk Saf Med. 1991;2(6):345–9. https://doi.org/10.3233/jrs-1991-2606.

Article  Google Scholar 

Mitchell AA, Gilboa SM, Werler MM, Kelley KE, Louik C, Hernández-Díaz S. Medication use during pregnancy, with particular focus on prescription drugs: 1976–2008. Am J Obstet Gynecol. 2011;205(1):e511–8. https://doi.org/10.1016/j.ajog.2011.02.029.

Article  Google Scholar 

Emanuel M, Rawlins M, Duff G, Breckenridge A. Thalidomide and its sequelae. Lancet (London England). 2012;380(9844):781–3. https://doi.org/10.1016/s0140-6736(12)60468-1.

Article  PubMed  Google Scholar 

Bjørk MH, Zoega H, Leinonen MK, et al. Association of Prenatal Exposure to antiseizure medication with risk of Autism and Intellectual Disability. JAMA Neurol. 2022;79(7):672–81. https://doi.org/10.1001/jamaneurol.2022.1269.

Article  PubMed  Google Scholar 

Diav-Citrin O, Shechtman S, Weinbaum D, et al. Paroxetine and fluoxetine in pregnancy: a prospective, multicentre, controlled, observational study. Br J Clin Pharmacol. 2008;66(5):695–705. https://doi.org/10.1111/j.1365-2125.2008.03261.x.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kmietowicz Z. Women are unaware of pregnancy risks linked with sodium valproate. BMJ (Clinical Res ed). 2016;355(i5829). https://doi.org/10.1136/bmj.i5829.

Mines D, Tennis P, Curkendall SM, et al. Topiramate use in pregnancy and the birth prevalence of oral clefts. Pharmacoepidemiol Drug Saf. 2014;23(10):1017–25. https://doi.org/10.1002/pds.3612.

Article  CAS  PubMed  Google Scholar 

Heyrana K, Byers HM, Stratton P. Increasing the participation of pregnant women in clinical trials. JAMA. 2018;320(20):2077–8. https://doi.org/10.1001/jama.2018.17716.

Article  PubMed  Google Scholar 

Huybrechts KF, Bateman BT, Hernández-Díaz S. Use of real-world evidence from healthcare utilization data to evaluate drug safety during pregnancy. Pharmacoepidemiol Drug Saf. 2019;28(7):906–22. https://doi.org/10.1002/pds.4789.

Article  PubMed  PubMed Central  Google Scholar 

U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER). Center for Biologics Evaluation and Research (CBER). Postapproval pregnancy safety studies guidance for industry. (2019-05). https://www.fda.gov/media/124746/download.

S. H-D. Pregnancy registries. In: AHRQ, ed. Registries for Evaluating Patient Outcomes: A User’s Guide: 3rd Edition 2014:135–168.

Administration FD. Guidance for industry: establishing pregnancy exposure registries. 2002. https://www.fda.gov/ucm/groups/fdagov-public/@fdagov-drugs-gen/documents/document/ucm071639.pdf.

Langhoff-Roos J, Krebs L, Klungsøyr K, et al. The nordic medical birth registers–a potential goldmine for clinical research. Acta Obstet Gynecol Scand. 2014;93(2):132–7. https://doi.org/10.1111/aogs.12302.

Article  PubMed  Google Scholar 

Charlton R, Snowball J, Sammon C, de Vries C. The Clinical Practice Research Datalink for drug safety in pregnancy research: an overview. Therapie. 2014;69(1):83–9. https://doi.org/10.2515/therapie/2014007.

Article  PubMed  Google Scholar 

Ailes EC, Simeone RM, Dawson AL, Petersen EE, Gilboa SM. Using insurance claims data to identify and estimate critical periods in pregnancy: an application to antidepressants. Birth defects research. Part A, clinical and molecular teratology. 2016;106(11):927–34. https://doi.org/10.1002/bdra.23573.

Bliddal M, Broe A, Pottegård A, Olsen J, Langhoff-Roos J. The Danish Medical Birth Register. Eur J Epidemiol. 2018;33(1):27–36. https://doi.org/10.1007/s10654-018-0356-1.

Article  PubMed  Google Scholar 

Pedersen LH, Petersen OB, Nørgaard M, et al. Linkage between the Danish National Health Service prescription database, the Danish fetal medicine database, and other Danish registries as a tool for the study of drug safety in pregnancy. Clin Epidemiol. 2016;8:91–5. https://doi.org/10.2147/clep.S98139.

Article  PubMed  PubMed Central  Google Scholar 

Zhu C, Yan L, Wang Y, Ji S, Zhang Y, Zhang J. Fertility intention and related factors for having a second or third child among childbearing couples in Shanghai, China. Front Public Health. 2022;10:879672. https://doi.org/10.3389/fpubh.2022.879672.

Article  PubMed  PubMed Central  Google Scholar 

Zhou Y, Mao X, Zhou H et al. Epidemiology of birth defects based on a birth defect surveillance system in Southern Jiangsu, China, 2014–2018. The journal of maternal-fetal & neonatal medicine: the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstet. 2022;35(4):745 – 51. https://doi.org/10.1080/14767058.2020.1731459.

Zhiwen Li JD, China CDC, Weekly, Foreword. Prevention and Control of Birth Defects in China: Achievements and Challenges. https://weekly.chinacdc.cn/en/article/doi/https://doi.org/10.46234/ccdcw2021.1912021.

Zhang X, Chen L, Wang X, et al. Changes in maternal age and prevalence of congenital anomalies during the enactment of China’s universal two-child policy (2013–2017) in Zhejiang Province, China: an observational study. PLoS Med. 2020;17(2):e1003047. https://doi.org/10.1371/journal.pmed.1003047.

Article  PubMed  PubMed Central  Google Scholar 

Liang J, Mu Y, Li X, et al. Relaxation of the one child policy and trends in caesarean section rates and birth outcomes in China between 2012 and 2016: observational study of nearly seven million health facility births. BMJ (Clinical Res ed). 2018;360:k817. https://doi.org/10.1136/bmj.k817.

Article  Google Scholar 

Dai L, Zhu J, Liang J, Wang YP, Wang H, Mao M. Birth defects surveillance in China. World J Pediatrics: WJP. 2011;7(4):302–10. https://doi.org/10.1007/s12519-011-0326-0.

Article  Google Scholar 

Yue W, Zhang E, Liu R, et al. The China birth cohort study (CBCS). Eur J Epidemiol. 2022;37(3):295–304. https://doi.org/10.1007/s10654-021-00831-8.

Article  PubMed  PubMed Central  Google Scholar 

Zhou Y, Tao J, Wang K, et al. Protocol of a prospective and multicentre China Teratology Birth Cohort (CTBC): association of maternal drug exposure during pregnancy with adverse pregnancy outcomes. BMC Pregnancy Childbirth. 2021;21(1):593. https://doi.org/10.1186/s12884-021-04073-0.

Article  PubMed  PubMed Central  Google Scholar 

Statistics XBo. Xiamen City 2021 National Economic and Social Development Statistical Bulletin. http://tjj.xm.gov.cn/tjzl/ndgb/202203/t20220322_2636525.htm. 2022.

National Health Committee of People‘s Republic of China. China Drug Supply Information Platform. 2018. http://cdsip.nhc.gov.cn/PriceBase/YPIDList.aspx? key¼ypid&value&#188.

National Health and Family Planning Commission of of People‘s Republic of China. Women’s health basic data set - part 6: birth defect surveillance, 2013. http://www.nhc.gov.cn/ewebeditor/uploadfile/2018/09/20180921141035465.pdf.

China Maternal and Child Health Serveillance. China birth defects surveillance system: Guidelines for reporting complicated and micro malformations. 2012., http://www.mchscn.org/admin/wenjian/wxjxbgbz-2012.pdf.

National Health Committee of People‘s Republic of China. 1 minute to understand the Congenital Structural Defects Program. 2019. http://www.nhc.gov.cn/fys/s3590/201903/9e08496ee740468a93764c4afd3ff4d8.shtml.

March of Dimes Birth Defects Foundation of China. Disease list of congenital metabolic defects program, 2017. http://www.csqx.org.cn/content.aspx? id¼381707814440.

Xie XKB, Duan T. Text book of Obstetrics and Gynecology (9th).Beijing: People’s medical publishing house2018.

Deng QYQH. Normative definition of stillbirth and related registration procedures. Chin J Practical Obstet Gynecol. 2015;31(10):925–6. Chinese.

Google Scholar 

Goldenberg RLCJ, Iams JD, Romero R. Epidemiology and causes of preterm birth. Lancet (London England). 2008;371:75–84. https://doi.org/10.1016/S0140-6736(08)60074-4.

Article  PubMed  Google Scholar 

Organization WH. International statistical classification of diseases and related health problems, 10th revision. https://icd.who.int/browse10/Content/statichtml/ICD10Volume2_en_2010.pdf. 2016.

Zhu Z, Yuan L, Wang J, et al. Mortality and morbidity of infants born extremely Preterm at Tertiary Medical Centers in China from 2010 to 2019. JAMA Netw open. 2021;4(5):e219382. https://doi.org/10.1001/jamanetworkopen.2021.9382.

Article  PubMed  PubMed Central  Google Scholar 

Marcus DM, Snodgrass WR. Do no harm: avoidance of herbal medicines during pregnancy. Obstet Gynecol. 2005;105(5 Pt 1):1119–22. https://doi.org/10.1097/01.AOG.0000158858.79134.ea.

Article  PubMed  Google Scholar 

Bruno LO, Simoes RS, de Jesus Simoes M, Girão M, Grundmann O. Pregnancy and herbal medicines: an unnecessary risk for women’s health-A narrative review. Phytother Res. 2018;32(5):796–810. https://doi.org/10.1002/ptr.6020.

Article  PubMed  Google Scholar 

Tazare J, Wyss R, Franklin JM, et al. Transparency of high-dimensional propensity score analyses: Guidance for diagnostics and reporting. Pharmacoepidemiol Drug Saf. 2022;31(4):411–23. https://doi.org/10.1002/pds.5412.

Article  PubMed  PubMed Central  Google Scholar 

National Bureau of Statistics of China. Statistical Monitoring Report of the Program for the Development of Chinese Women (2021–2030), 2021. https://www.stats.gov.cn/sj/zxfb/202312/t20231229_1946062.html.